Merck & Co (NY:MRK)

The healthcare sector experienced a significant downturn on Thursday, September 25, 2025, shedding a notable -1.67% of its value and sending ripples of concern through the broader financial markets....

Topics Economy Intellectual Property

Healthcare Sector Reels: A Deep Dive into Thursday's -1.67% Plunge

September 26, 2025

Pharmaceutical Tariffs ‘A Light At The End Of The Trump Tunnel’ For Big Pharma, Says Jefferies ↗

Topics Economy

September 26, 2025

Topics Government

Evaxion Stock Jumps A Whopping 43% Pre-Market – Here’s What Happened ↗

September 25, 2025

Merck Says EMA Committee Adopted Two Positive Opinions For Expanding Use Of Cancer Drug Keytruda ↗

Price Over Earnings Overview: Merck & Co ↗

September 22, 2025

Via Benzinga

September 19, 2025

Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet ↗

September 26, 2025

Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de

Via Benzinga

Topics Government World Trade

Prediction: 2 Stocks That Will Be Worth More Than BigBear.ai 5 Years From Now ↗

September 26, 2025

BigBear.ai is bigger than both of these AI-focused companies now. That could change.

Robert F. Kennedy Jr. Faces Impeachment Push From Haley Stevens Over 'Health Care Chaos' And Rising Costs: 'Enough Is Enough' ↗

Topics Artificial Intelligence

September 26, 2025

Rep. Haley Stevens (D-Mich.) announced that she will introduce articles of impeachment against Health and Human Services Secretary Robert F. Kennedy Jr.

Via Benzinga

Trump Shocks Pharma With 100% Tariff On Imported Drugs Unless Companies Build In America ↗

September 25, 2025

Moderna Stands By UK As Pharma Giants Criticize Pricing, UK Secures First Onshore mRNA Vaccine Production Centre ↗

Topics Government

September 25, 2025

Moderna, Inc.‘s (NASDAQ: MRNA) UK chief Darius Hughes defended Britain's drug pricing policies after the country was branded the "worst in Europe."

Via Benzinga

Peering Into Merck & Co's Recent Short Interest ↗

September 25, 2025

Merck & Co's (NYSE: MRK) short interest as a percent of float has risen 16.98% since its last report. According to exchange reported data, there are now 27.71 million shares sold short, which is 1.24%...

Via Benzinga

Merck & Co. Inc. (NYSE:MRK): A Prime Candidate for a Dependable Dividend Portfolio ↗

September 25, 2025

Merck & Co. (MRK) offers a solid 3.97% dividend yield with a strong history of growth. Its reliable payout is backed by excellent profitability and a healthy balance sheet, making it a top choice for...

Via Chartmill

United Kingdom The Worst European Country For Drug Prices: Eli Lilly CEO ↗

September 24, 2025

Eli Lilly CEO Dave Ricks criticizes UK drug pricing and rebate rules as pharma giants scale back investments, warning of fewer new medicines.

Via Benzinga

The Smartest Dividend Stock to Buy With $1,000 Right Now ↗

September 24, 2025

Drug makers are out of favor right now, but the industry will survive. Here's one company that stands out as an investment option.

Pfizer has a huge yield right now, but it might make more sense for dividend investors to step down in yield to these two alternatives.

Topics Intellectual Property

Should You Forget Pfizer and Buy These Unstoppable Stocks Instead? ↗

September 24, 2025

All three of these names are not only built to last, they're being rebuilt to thrive for at least a few more decades.

Topics Intellectual Property

3 Dividend Stocks Perfect for Millennial Investors ↗

September 24, 2025

The Magnificent Seven tech giants are now worth $21 trillion—8x more than top health care stocks, echoing dot-com bubble extremes.

Topics Economy Intellectual Property Retirement

The Magnificent 7 Boom Just Triggered A Dot-Com Era Warning ↗

September 23, 2025

Via Benzinga

Trump Advises Parents To Split Vaccines, Delay Hepatitis B Shots Until Age 12: 'This Is Based On What I Feel' ↗

September 22, 2025

President Donald Trump on Monday offered advice on childhood vaccination schedules, encouraging parents to split up certain immunizations and delay certain others, in sharp contradiction to current...

Via Benzinga

Topics Government

Inflation's Lingering Shadow: Long-Term Expectations Rise Amidst Fed Rate Cuts

September 22, 2025

The financial markets are currently navigating a perplexing economic landscape where long-term inflation expectations are on the rise, even as the Federal Reserve initiates interest rate cuts. In...

FDA approves Merck's Keytruda Qlex injection for adults with solid tumors. Merck expects it to be available in the U.S. in September.

Topics Bonds ETFs Economy

FDA Clears Merck's One-Minute Cancer Shot ↗

September 22, 2025

Via Benzinga

Growth Titans: Eli Lilly's Weight-Loss Surge vs. Johnson & Johnson's Diversified Might

September 22, 2025

The pharmaceutical landscape is currently a tale of two giants employing vastly different, yet highly successful, growth strategies. Eli Lilly and Company (NYSE: LLY) has placed an extraordinary bet on...

But that doesn't mean Keytruda is safe from the looming patent cliff.

Topics Artificial Intelligence Economy Intellectual Property

Merck Snags A Key Approval Before Its Cash Cow Goes Off A Patent Cliff ↗

September 22, 2025

Via Investor's Business Daily

Topics Intellectual Property

3 Dirt-Cheap Stocks to Buy Right Now ↗

September 22, 2025

These stocks share several common denominators, including attractive valuations.

A high yield is only one part of the story when it comes to picking dividend stocks.

Topics Intellectual Property

What Is Considered a Good Stock Dividend? 3 Healthcare Stocks That Fit the Bill ↗

September 20, 2025

FDA Approves Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for KEYTRUDA® (pembrolizumab)

Topics Intellectual Property

September 19, 2025

From Merck & Co., Inc.

Via Business Wire

Merck Scores Positive Feedback From EU Agency Regarding Blockbuster Cancer Drug ↗

September 19, 2025

Merck received positive Keytruda notes from CHMP regarding its breakthrough cancer treatment with final decisions expected in late 2025.

Via Benzinga

Lilly's Oncology Momentum Soars: Olomorasib Gains Breakthrough Status, Jaypirca Achieves Landmark Clinical Successes

September 19, 2025

Eli Lilly and Company (NYSE: LLY) is making significant waves in the oncology landscape with a series of major announcements concerning two of its innovative cancer therapies: Olomorasib and Jaypirca...